Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it
works when given together with ivosidenib with or without azacitidine, in treating patients
with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving ivosidenib and venetoclax with azacitidine may work better in treating
patients with hematologic malignancies compared to ivosidenib and venetoclax alone.